Evidence of clinical benefit of WHO essential anticancer medicines for children, 2011-2021

Lin Bai; Yuqi Zhan; Yue Zhou; Yichen Zhang; Luwen Shi; Sumit Gupta; Avram Denburg; Xiaodong Guan

doi:10.1016/j.eclinm.2023.101966

Evidence of clinical benefit of WHO essential anticancer medicines for children, 2011-2021

EClinicalMedicine. 2023 Apr 12:59:101966. doi: 10.1016/j.eclinm.2023.101966. eCollection 2023 May.

Authors

Lin Bai¹, Yuqi Zhan¹, Yue Zhou^{1

2}, Yichen Zhang¹, Luwen Shi^{1

3}, Sumit Gupta^{4

5}, Avram Denburg^{4

5}, Xiaodong Guan^{1

3}

Affiliations

¹ Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Sciences, Peking University, Beijing, 100191, China.
² Department of Pharmacy, Peking University People's Hospital, Beijing, 100044, China.
³ International Research Center for Medicinal Administration, Peking University, Beijing, 100191, China.
⁴ Division of Haematology/Oncology, Hospital for Sick Children, Toronto, ON, M5G 1X8, Canada.
⁵ Department of Paediatrics, Faculty of Medicine, University of Toronto, Toronto, ON, M5G 1X8, Canada.

Abstract

Background: Access to essential cancer medicines is a key determinant of childhood cancer survival. WHO published the Model List of Essential Medicine for Children (EMLc) and updated it every two years since 2007 to promote better access to medicines for children. This study aimed to assess whether the inclusion of essential anticancer medicines for respective indications for children was based on evidence of significant clinical benefit between 2011 and 2021.

Methods: We identified all anticancer medicine indications added to the WHO EMLc Section 8 since 2011 and extracted evidence of benefit documented in the corresponding technical reports. Evidence in children was defined as evidence that included participants under 12, and graded into five levels, according to the Oxford Centre for Evidence-Based Medicine Levels of Evidence. We analyzed whether each anticancer medicine indication was listed with documented OS benefit or improvements in surrogate measures based on the highest level of documented evidence in children.

Findings: A total of 115 anticancer medicine indications were added to the EMLc from 2011 to 2021, of which 101 (87.8%) had some clinical evidence in children and 4 (3.5%) were added without any clinical evidence. Among the 101 medicine indications, none were added with level-1 evidence in children, and 43 (42.6%), 11 (10.9%), 41 (40.6%), and 6 (5.9%) were listed with level-2, level-3, level-4, and level-5 evidence in children, respectively. Only eight (7.9%) medicine indications were reported to have OS benefit, another 12 (11.9%) were reported to have improvements on surrogate measures, and 81 (80.2%) were listed in the EMLc without documented improvements in either OS or surrogate measures.

Interpretation: Most anticancer medicine indications of the WHO EMLc were added based on limited evidence of statistically significant clinical benefit in children. Our results suggest that WHO should refine requirements for clinical benefit criteria and permissible forms, quality, and reporting of evidence of essential anticancer medicines for children, specify whether anticancer medicine indications have required evidence of clinical benefit in children, and provide further details in its technical reports that summarise the available evidence.

Funding: Not applicable.

Keywords: Cancer drugs; Children; Essential medicines; Evidence; World Health Organization.